Invasive fungal infections in liver transplantation

International Journal of Infectious Diseases

Volumn 15, Issue 5, 2011, Pages

  Liu, Xia ^a   Ling, Zongxin ^a   Li, Lanjuan ^a   Ruan, Bing ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Aspergillus; Candida; Cryptococcus neoformans; Fungal infection; Histoplasma capsulatum; Liver transplantation

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CLOTRIMAZOLE; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; NYSTATIN; VORICONAZOLE;

ASPERGILLOSIS; CANDIDIASIS; CRYPTOCOCCOSIS; GRAFT RECIPIENT; HISTOPLASMOSIS; HUMAN; LIVER TRANSPLANTATION; MOLECULAR DIAGNOSIS; REVIEW; RISK FACTOR; SYSTEMIC MYCOSIS;

ANTIFUNGAL AGENTS; EARLY DIAGNOSIS; FUNGI; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; LIVER TRANSPLANTATION; MOLECULAR DIAGNOSTIC TECHNIQUES; MYCOSES; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 79954616092     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2011.01.005     Document Type: Review

References (70)

1. Reed A., Herndon J.B., Ersoz N., Fujikawa T., Schain D., Lipori P., et al. Effect of prophylaxis on fungal infection and costs for high-risk liver transplant recipients. Liver Transpl 2007, 13:1743-1750.
2. Rosenhagen M., Feldhues R., Schmidt J., Hoppe-Tichy T., Geiss H.K. A risk profile for invasive aspergillosis in liver transplant recipients. Infection 2009, 37:313-319.
3. Singh N., Wagener M.M., Marino I.R., Gayowski T. Trends in invasive fungal infections in liver transplant recipients: correlation with evolution in transplantation practices. Transplantation 2002, 73:63-67.
4. Eschenauer G.A., Lam S.W., Carver P.L. Antifungal prophylaxis in liver transplant recipients. Liver Transpl 2009, 15:842-858.
5. Grauhan O., Lohmann R., Lemmens P., Schattenfroh N., Keck H., Klein E., et al. Fungal infections in liver transplant recipients. Langenbecks Arch Chir 1994, 379:372-375.
6. Paya C.V. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993, 16:677-688.
7. Singh N. Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am 2003, 17:113-134. viii.
8. Wajszczuk C.P., Dummer J.S., Ho M., Van Thiel D.H., Starzl T.E., Iwatsuki S., et al. Fungal infections in liver transplant recipients. Transplantation 1985, 40:347-353.
9. Singh N., Paterson D.L. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005, 18:44-69.
10. Briegel J., Forst H., Spill B., Haas A., Grabein B., Haller M., et al. Risk factors for systemic fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 1995, 14:375-382.
11. Verma A., Wade J.J., Cheeseman P., Samaroo B., Rela M., Heaton N.D., et al. Risk factors for fungal infection in paediatric liver transplant recipients. Pediatr Transplant 2005, 9:220-225.
12. Singh N., Pruett T.L., Houston S., Munoz P., Cacciarelli T.V., Wagener M.M., et al. Invasive aspergillosis in the recipients of liver retransplantation. Liver Transpl 2006, 12:1205-1209.
13. Shi S.H., Lu A.W., Shen Y., Jia C.K., Wang W.L., Xie H.Y., et al. Spectrum and risk factors for invasive candidiasis and non-Candida fungal infections after liver transplantation. Chin Med J (Engl) 2008, 121:625-630.
14. Rabkin J.M., Oroloff S.L., Corless C.L., Benner K.G., Flora K.D., Rosen H.R., et al. Association of fungal infection and increased mortality in liver transplant recipients. Am J Surg 2000, 179:426-430.
15. Patel R., Portela D., Badley A.D., Harmsen W.S., Larson-Keller J.J., Ilstrup D.M., et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 1996, 62:926-934.
16. Osawa M., Ito Y., Hirai T., Isozumi R., Takakura S., Fujimoto Y., et al. Risk factors for invasive aspergillosis in living donor liver transplant recipients. Liver Transpl 2007, 13:566-570.
17. Kusne S., Blair J.E. Viral and fungal infections after liver transplantation-part II. Liver Transpl 2006, 12:2-11.
18. Gavalda J., Len O., San Juan R., Aguado J.M., Fortun J., Lumbreras C., et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 2005, 41:52-59.
19. Fortun J., Martin-Davila P., Moreno S., De Vicente E., Nuno J., Candelas A., et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl 2002, 8:1065-1070.
20. Cruciani M., Mengoli C., Malena M., Bosco O., Serpelloni G., Grossi P. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl 2006, 12:850-858.
21. Singh N., Avery R.K., Munoz P., Pruett T.L., Alexander B., Jacobs R., et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 2003, 36:46-52.
22. Cuellar-Rodriguez J., Avery R.K., Lard M., Budev M., Gordon S.M., Shrestha N.K., et al. Histoplasmosis in solid organ transplant recipients: 10years of experience at a large transplant center in an endemic area. Clin Infect Dis 2009, 49:710-716.
23. Fung J.J. Fungal infection in liver transplantation. Transpl Infect Dis 2002, 4(Suppl 3):18-23.
24. Husain S., Tollemar J., Dominguez E.A., Baumgarten K., Humar A., Paterson D.L., et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 2003, 75:2023-2029.
25. Karchmer A.W., Samore M.H., Hadley S., Collins L.A., Jenkins R.L., Lewis W.D. Fungal infections complicating orthotopic liver transplantation. Trans Am Clin Climatol Assoc 1995, 106:38-47. discussion 47-8.
26. Paya C.V. Prevention of fungal and hepatitis virus infections in liver transplantation. Clin Infect Dis 2001, 33(Suppl 1):S47-52.
27. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
28. Muñoz P., Guinea J., Bouza E. Update on invasive aspergillosis: clinical and diagnostic aspects. Clin Microbiol Infect 2006, 12:24-39.
29. Maertens J., Van Eldere J., Verhaegen J., Verbeken E., Verschakelen J., Boogaerts M. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 2002, 186:1297-1306.
30. Maertens J., Verhaegen J., Lagrou K., Van Eldere J., Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001, 97:1604-1610.
31. Mennink-Kersten M.A., Donnelly J.P., Verweij P.E. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004, 4:349-357.
32. Latge J.P., Moutaouakil M., Debeaupuis J.P., Bouchara J.P., Haynes K., Prevost M.C. The 18-kilodalton antigen secreted by Aspergillus fumigatus. Infect Immun 1991, 59:2586-2594.
33. Pazos C., Ponton J., Del Palacio A. Contribution of (1->3)-beta-d-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005, 43:299-305.
34. Arnow P.M., Carandang G.C., Zabner R., Irwin M.E. Randomized controlled trial of selective bowel decontamination for prevention of infections following liver transplantation. Clin Infect Dis 1996, 22:997-1003.
35. Hellinger W.C., Yao J.D., Alvarez S., Blair J.E., Cawley J.J., Paya C.V., et al. A randomized, prospective, double-blinded evaluation of selective bowel decontamination in liver transplantation. Transplantation 2002, 73:1904-1909.
36. Rosman C., Klompmaker I.J., Bonsel G.J., Bleichrodt R.P., Arends J.P., Slooff M.J. The efficacy of selective bowel decontamination as infection prevention after liver transplantation. Transplant Proc 1990, 22:1554-1555.
37. Zwaveling J.H., Maring J.K., Klompmaker I.J., Haagsma E.B., Bottema J.T., Laseur M., et al. Selective decontamination of the digestive tract to prevent postoperative infection: a randomized placebo-controlled trial in liver transplant patients. Crit Care Med 2002, 30:1204-1209.
38. Sharpe M.D., Ghent C., Grant D., Horbay G.L., McDougal J., David Colby W. Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study. Transplantation 2003, 76:977-983.
39. Singhal S., Ellis R.W., Jones S.G., Miller S.J., Fisher N.C., Hastings J.G., et al. Targeted prophylaxis with amphotericin B lipid complex in liver transplantation. Liver Transpl 2000, 6:588-595.
40. Fortun J., Martin-Davila P., Moreno S., Barcena R., de Vicente E., Honrubia A., et al. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother 2003, 52:813-819.
41. Winston D.J., Pakrasi A., Busuttil R.W. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999, 131:729-737.
42. Winston D.J., Busuttil R.W. Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation 2002, 74:688-695.
43. Fortun J., Martin-Davila P., Montejo M., Munoz P., Cisneros J.M., Ramos A., et al. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation 2009, 87:424-435.
44. Playford E.G., Webster A.C., Sorrell T.C., Craig J.C. Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 2006, 25:549-561.
45. Singh N., Wagener M.M., Cacciarelli T.V., Levitsky J. Antifungal management practices in liver transplant recipients. Am J Transplant 2008, 8:426-431.
46. Nguyen M.H., Peacock J.E., Morris A.J., Tanner D.C., Nguyen M.L., Snydman D.R., et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996, 100:617-623.
47. Rocco T.R., Reinert S.E., Simms H.H. Effects of fluconazole administration in critically ill patients: analysis of bacterial and fungal resistance. Arch Surg 2000, 135:160-165.
48. Tollemar J., Hockerstedt K., Ericzon B.G., Jalanko H., Ringden O. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study. Transplantation 1995, 59:45-50.
49. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
50. Badley A.D., Seaberg E.C., Porayko M.K., Wiesner R.H., Keating M.R., Wilhelm M.P., et al. Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database. Transplantation 1997, 64:66-73.
51. Singh N., Arnow P.M., Bonham A., Dominguez E., Paterson D.L., Pankey G.A., et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 1997, 64:716-720.
52. Kusne S., Torre-Cisneros J., Manez R., Irish W., Martin M., Fung J., et al. Factors associated with invasive lung aspergillosis and the significance of positive Aspergillus culture after liver transplantation. J Infect Dis 1992, 166:1379-1383.
53. Linden P.K., Coley K., Fontes P., Fung J.J., Kusne S. Invasive aspergillosis in liver transplant recipients: outcome comparison of therapy with amphotericin B lipid complex and a historical cohort treated with conventional amphotericin B. Clin Infect Dis 2003, 37:17-25.
54. Denning D.W., Ribaud P., Milpied N., Caillot D., Herbrecht R., Thiel E., et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002, 34:563-571.
55. Vilchez R.A., Fung J., Kusne S. Cryptococcosis in organ transplant recipients: an overview. Am J Transplant 2002, 2:575-580.
56. Singh N., Dromer F., Perfect J.R., Lortholary O. Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis 2008, 47:1321-1327.
57. Singh N., Forrest G. Cryptococcosis in solid organ transplant recipients. Am J Transplant 2009, 9(Suppl 4):S192-S198.
58. Husain S., Wagener M.M., Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis 2001, 7:375-381.
59. Vilchez R., Shapiro R., McCurry K., Kormos R., Abu-Elmagd K., Fung J., et al. Longitudinal study of cryptococcosis in adult solid-organ transplant recipients. Transpl Int 2003, 16:336-340.
60. Perfect J.R., Dismukes W.E., Dromer F., Goldman D.L., Graybill J.R., Hamill R.J., et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010, 50:291-322.
61. Shallot J., Pursell K.J., Bartolone C., Williamson P., Benedetti E., Layden T.J., et al. Disseminated histoplasmosis after orthotopic liver transplantation. Liver Transpl Surg 1997, 3:433-434.
62. Kauffman C.A. Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev 2007, 20:115-132.
63. Wheat L.J., Conces D., Allen S.D., Blue-Hnidy D., Loyd J. Pulmonary histoplasmosis syndromes: recognition, diagnosis, and management. Semin Respir Crit Care Med 2004, 25:129-144.
64. Wheat J., Sarosi G., McKinsey D., Hamill R., Bradsher R., Johnson P., et al. Practice guidelines for the management of patients with histoplasmosis. Infectious Diseases Society of America. Clin Infect Dis 2000, 30:688-695.
65. Botterel F., Romand S., Saliba F., Reynes M., Bismuth H., Samuel D., et al. A case of disseminated histoplasmosis likely due to infection from a liver allograft. Eur J Clin Microbiol Infect Dis 1999, 18:662-664.
66. Vinayek R., Balan V., Pinna A., Linden P.K., Kusne S. Disseminated histoplasmosis in a patient after orthotopic liver transplantation. Clin Transplant 1998, 12:274-277.
67. Oh Y.S., Lisker-Melman M., Korenblat K.M., Zuckerman G.R., Crippin J.S. Disseminated histoplasmosis in a liver transplant recipient. Liver Transpl 2006, 12:677-681.
68. Freifeld A.G., Iwen P.C., Lesiak B.L., Gilroy R.K., Stevens R.B., Kalil A.C. Histoplasmosis in solid organ transplant recipients at a large Midwestern university transplant center. Transpl Infect Dis 2005, 7:109-115.
69. Kauffman C.A. Diagnosis of histoplasmosis in immunosuppressed patients. Curr Opin Infect Dis 2008, 21:421-425.
70. Wheat L.J., Freifeld A.G., Kleiman M.B., Baddley J.W., McKinsey D.S., Loyd J.E., et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007, 45:807-825.